[go: up one dir, main page]

AR044054A1 - Sales de risperidona solubles en agua - Google Patents

Sales de risperidona solubles en agua

Info

Publication number
AR044054A1
AR044054A1 ARP040101358A ARP040101358A AR044054A1 AR 044054 A1 AR044054 A1 AR 044054A1 AR P040101358 A ARP040101358 A AR P040101358A AR P040101358 A ARP040101358 A AR P040101358A AR 044054 A1 AR044054 A1 AR 044054A1
Authority
AR
Argentina
Prior art keywords
risperidone
salt
water
risperidona
solubles
Prior art date
Application number
ARP040101358A
Other languages
English (en)
Inventor
Reinerus Gerardus Gieling
Desiree Laurant
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of AR044054A1 publication Critical patent/AR044054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a una sal de risperidona de fórmula (1) en estado sólido que tiene una solubilidad en agua de al menos 10 mg/ml, al dihidrocloruro de risperidona, hidrogenomaleato de risperidona, hemitartrato de risperidona y (L)-hemimalato de risperidona, a un proceso para prepara una sal soluble en agua de risperidona en estado sólido, que comprende: hacer contactar un donante de risperidona con un ácido adecuado en un solvente orgánico para formar una sal de risperidona soluble en agua; y hacer precipitar dicha sal de risperidona a partir de dicho solvente y a su utilización para tratar trastornos psicóticos en un mamífero.
ARP040101358A 2003-04-22 2004-04-22 Sales de risperidona solubles en agua AR044054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46436403P 2003-04-22 2003-04-22

Publications (1)

Publication Number Publication Date
AR044054A1 true AR044054A1 (es) 2005-08-24

Family

ID=33310877

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP040101358A AR044054A1 (es) 2003-04-22 2004-04-22 Sales de risperidona solubles en agua
ARP040101359A AR044055A1 (es) 2003-04-22 2004-04-22 Monohidrocloruro de risperidona

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP040101359A AR044055A1 (es) 2003-04-22 2004-04-22 Monohidrocloruro de risperidona

Country Status (5)

Country Link
US (2) US20040266791A1 (es)
EP (2) EP1615923A1 (es)
AR (2) AR044054A1 (es)
NO (2) NO20055490L (es)
WO (2) WO2004094415A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
EP2405967B1 (en) * 2009-03-12 2020-09-23 Delpor, Inc. Implantable device for long-term delivery of drugs
US9446135B2 (en) 2011-04-25 2016-09-20 Shandong Luye Pharmaceutical Co., Ltd. Risperidone sustained release microsphere composition
WO2012147035A1 (en) 2011-04-26 2012-11-01 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
CN105163719B (zh) 2013-03-11 2019-03-08 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
WO2016149561A1 (en) * 2015-03-17 2016-09-22 Oak Crest Institute Of Science Subdermal implants for the sustained delivery of water-soluble drugs
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
WO2023233051A1 (es) 2022-05-18 2023-12-07 Laboratorios Farmacéuticos Rovi, S.A. Composiciones inyectables de liberación prolongada para su uso en el tratamiento con risperidona junto a inhibidores de la enzima cyp2d6

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4443451A (en) * 1981-07-15 1984-04-17 Janssen Pharmaceutica N.V. Bicyclic pyrimidin-5-one derivatives
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation

Also Published As

Publication number Publication date
NO20055485D0 (no) 2005-11-21
NO20055485L (no) 2006-01-23
EP1615923A1 (en) 2006-01-18
NO20055490D0 (no) 2005-11-21
WO2004094414A1 (en) 2004-11-04
US20040266790A1 (en) 2004-12-30
NO20055490L (no) 2006-01-23
WO2004094415A1 (en) 2004-11-04
EP1615924A1 (en) 2006-01-18
US20040266791A1 (en) 2004-12-30
AR044055A1 (es) 2005-08-24

Similar Documents

Publication Publication Date Title
AR044054A1 (es) Sales de risperidona solubles en agua
ES2561108T3 (es) Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
GT199800113A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
PE20030581A1 (es) Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo
PE20001049A1 (es) Complejos estables de compuestos escasamente solubles
WO2006122806A3 (en) 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
CY1110800T1 (el) Μεθανοσουλφονικα αλατα αβιρατερονης-3-εστερων και ανακτηση αλατων αβιρατερονης-3-εστερων απο διαλυμα σε μεθυλο τριτ-βουτυλαιθερα
BR0307330A (pt) Produção do delta-9-tetraidrocanabinol
CO6260141A2 (es) Inhibidores del co-transportador 2 sodio glucosa y metodos para la preparacion de los mismos y sus intermediarios
IL213613A (en) History of pirazine, preparations containing them and their uses
JO2256B1 (en) Renin inhibitors
CO6241152A2 (es) 3-(imidazolil)-pirazolo[3, 4-b] piridinas
AR051404A1 (es) Composiciones de limpieza y desinfectantes
MX2010003603A (es) Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
AR034370A1 (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral
JP2019517990A5 (es)
PE20040767A1 (es) Derivado hemisulfato de azido citosina cristalino anhidro
EA201070228A1 (ru) Тразодон и гидрохлорид тразодона в очищенной форме
PE20080365A1 (es) Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
IN2014KN01308A (es)
AR067048A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal